Rash News and Research

RSS

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Janssen Research & Development, LLC today announced positive results from a pivotal Phase 2 global registration study (MCD2001) suggesting siltuximab, an investigational compound, along with best supportive care, exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in treating patients with the rare disorder Multicentric Castleman's Disease who are HIV-negative and human herpes virus 8-negative.

8 Dec 2013

College students not only bring dirty socks but also mononucleosis to home

One of the hallmarks of heading home for winter break is the enormous amounts of laundry college students bring as a welcome home present for Mom and Dad. But the dirty socks might not be the only unwelcome guest they transport home. They might also bring mononucleosis, better known as mono.

6 Dec 2013

Measles still poses threat to domestic and global health security

Fifty years after the approval of an extremely effective vaccine against measles, one of the world's most contagious diseases, the virus still poses a threat to domestic and global health security.

5 Dec 2013

Investigational c-Met inhibitor shows early promise in NSCLC

A first-in-class drug that inhibits c-Met, a receptor tyrosine kinase, has demonstrated good tolerability when combined with erlotinib in the treatment of Japanese patients with advanced/metastatic non-small-cell lung cancer.

3 Dec 2013

Four-drug regimen shows first-line efficacy in advanced NSCLC

A four-drug combination of cetuximab, bevacizumab, carboplatin, and paclitaxel is effective and has acceptable safety as a first-line treatment for advanced non-small-cell lung cancer, US researchers report.

2 Dec 2013

Icahn School of Medicine receives $2.7M to investigate narrow pathway targeted immune therapy

The National Institutes of Health has awarded a research team at the Icahn School of Medicine at Mount Sinai $2.7 million to study systemic treatments for patients with moderate to severe atopic dermatitis (AD), also known as eczema.

26 Nov 2013

People with food allergy more likely to be murdered than to die from severe reaction

A person with a food allergy is more likely to be murdered than to die from a severe reaction, according to a new study.

25 Nov 2013

EC approves INVOKANA (canagliflozin) medication for adults with type 2 diabetes mellitus

Janssen-Cilag International NV announced today that the European Commission has approved INVOKANA (canagliflozin) in the European Union for the treatment of adults with type 2 diabetes mellitus, to improve glycaemic control[1]. Canagliflozin is an oral, once-daily medication, which belongs to a new class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors.

23 Nov 2013

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.

23 Nov 2013

New hope for patients whose melanoma has metastasised to the brain

New data show that in patients whose melanoma (BRAF V600 mutation-positive) has spread (metastasised) to the brain, Zelboraf (vemurafenib) extends life expectancy by over six months compared to chemotherapy.1 These results are welcome news for patients suffering from metastatic melanoma, as up to half of these patients are diagnosed with brain metastases with many given less than six months to live.1

18 Nov 2013

Congressional Democrats fuming at White House handling of health law

An increasing number of these lawmakers say they favor a legislative plan offered by Sen. Mary Landrieu of Louisiana to allow people whose insurance has been canceled because of the law to keep it.

15 Nov 2013

Imbruvica gets FDA approval for treatment of mantle cell lymphoma

The U.S. Food and Drug Administration today approved Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma, a rare and aggressive type of blood cancer.

13 Nov 2013

Dermatologist offers tips for healthy hair when using hair treatments

While coloring your hair is a common beauty treatment, the process can leave your hair dry and brittle. Fortunately, dermatologists, who are experts in the care of the skin, hair and nails, offer tips for coloring and perming your hair while keeping it healthy.

13 Nov 2013

Pivotal Phase III STARTVerso data shows efficacy of faldaprevir in genotype-1 infected HCV patients

Boehringer Ingelheim today announced new data from its Phase III clinical trial programme, STARTVerso, which evaluates faldaprevir in combination with pegylated interferon and ribavirin (PegIFN/RBV).

5 Nov 2013

Experimental drug effective in treating patients with non-small cell lung cancer

An experimental cancer drug that has shown promise in the treatment of melanoma has also shown early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death among men and women worldwide.

4 Nov 2013

Toxicity limits benefits of bevacizumab–erlotinib NSCLC maintenance therapy

Two targeted anticancer drugs used together after first-line chemotherapy for advanced stage non-small-cell lung cancer improve progression-free survival, the results of a large, prospective study show.

31 Oct 2013

Interim data from Phase 1B trial of an investigational anti-PD-1 immunotherapy in patients with previously-treated NSCLC announced by Merck

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced the presentation of interim data from a Phase 1B trial (PN001) evaluating MK-3475, an investigational anti-PD-1 immunotherapy, in patients with previously-treated non-small cell lung cancer (NSCLC). The data were presented today by Dr. Edward Garon, Director of Thoracic Oncology, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, at the 15th World Conference on Lung Cancer in Sydney, Australia (Abstract #2416).

31 Oct 2013

ARIAD temporarily suspends commercial distribution of Iclusig drug in US

ARIAD Pharmaceuticals, Inc. today announced that it is temporarily suspending the marketing and commercial distribution of Iclusig® (ponatinib), a treatment for patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL), in the United States, while it continues to negotiate updates to the U.S. prescribing information for Iclusig and implementation of a risk mitigation strategy.

31 Oct 2013

Researchers find more accurate method to screen for meningococcal infection

Researchers from the University of Missouri School of Medicine have found a more accurate method to screen for bacterial meningococcal infection in its early stages, when it's hardest to detect. According to the researchers, the method for diagnosis could save lives by getting patients treatment earlier, when the infection is most treatable.

31 Oct 2013

Promising melanoma drug demonstrates potential for non-small cell lung cancer treatment

An experimental new cancer drug called MK-3475, which has shown dramatic promise for treating melanoma is also showing early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death of men and women worldwide.

30 Oct 2013

Rash News and Research

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

College students not only bring dirty socks but also mononucleosis to home

Measles still poses threat to domestic and global health security

Investigational c-Met inhibitor shows early promise in NSCLC

Four-drug regimen shows first-line efficacy in advanced NSCLC

Icahn School of Medicine receives $2.7M to investigate narrow pathway targeted immune therapy

People with food allergy more likely to be murdered than to die from severe reaction

EC approves INVOKANA (canagliflozin) medication for adults with type 2 diabetes mellitus

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

New hope for patients whose melanoma has metastasised to the brain

Congressional Democrats fuming at White House handling of health law

Imbruvica gets FDA approval for treatment of mantle cell lymphoma

Dermatologist offers tips for healthy hair when using hair treatments

Pivotal Phase III STARTVerso data shows efficacy of faldaprevir in genotype-1 infected HCV patients

Experimental drug effective in treating patients with non-small cell lung cancer

Toxicity limits benefits of bevacizumab–erlotinib NSCLC maintenance therapy

Interim data from Phase 1B trial of an investigational anti-PD-1 immunotherapy in patients with previously-treated NSCLC announced by Merck

ARIAD temporarily suspends commercial distribution of Iclusig drug in US

Researchers find more accurate method to screen for meningococcal infection

Promising melanoma drug demonstrates potential for non-small cell lung cancer treatment

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News